article thumbnail

Advances in cell line development

Drug Discovery World

Grand View Research states that the market for cell lines is currently bolstered by the fact that the majority of biopharma companies use cell lines to synthesise recombinant monoclonal antibodies and proteins. Looking towards the future Technological advances are helping drive efficiencies in cell line development.

article thumbnail

Biologic Therapeutics Development, Part 1: Definition and Distinct Characteristics

Camargo

Recombinant therapeutic proteins. Fusion proteins. Monoclonal antibodies (mAbs). They are often heat sensitive, membrane impermeable, subject to enzymatic degradation, and susceptible to microbial contamination (a factor which impacts manufacturing steps and quality considerations). Gene and cellular therapies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

While there is no evidence of person-to-person transmission, anthrax skin lesions may be contagious through direct contact or contaminated objects. The bacteria usually enter the body through wounds, but infection can also occur through contaminated meat or inhalation of spores. Overall, 66.3 on Day 64 in the study. anthracis exposure.

article thumbnail

Nanofiber technology enabling the future of CGT bioprocessing

Drug Discovery World

Current processes rely on solutions developed for monoclonal antibodies that are not fit for purpose for viral vector purification, resulting in low yields, long processing times, and high costs. Minimising host cell protein (HCP) contamination is important for limiting immunogenicity, even at laboratory scale.

article thumbnail

Biopharmaceutical Filtration: A Deep Dive

Roots Analysis

Biopharmaceutical filtration is a critical step in the production of biopharmaceuticals, including proteins, antibodies, and vaccines. It involves the separation of unwanted particles from biological materials to obtain contaminant free products. Particle Removal: This is the primary function of these filtration systems.

article thumbnail

Can your LNP manufacturing platform cope with the pace of the mRNA revolution?

Pharmaceutical Technology

Every stage of development should result in a reproducible, safe drug product with no cross contamination from one batch to another. Almost 20 years later, the benefits of SUT are well recognised in the manufacture of monoclonal antibodies and biopharmaceutical manufacturing in general.

article thumbnail

HPAPIs – Current Interest of the Pharmaceutical Industry

Roots Analysis

As the global market for pharmaceutical solutions is increasing, pressure to bring biological APIs in different biological forms is rising and with the rising demand of targeted therapies, antibody-drug conjugates (ADCs) and cytotoxic drugs have gained wide attention in the field of HPAPIs.